IL261792B - Preparations - Google Patents
PreparationsInfo
- Publication number
- IL261792B IL261792B IL261792A IL26179218A IL261792B IL 261792 B IL261792 B IL 261792B IL 261792 A IL261792 A IL 261792A IL 26179218 A IL26179218 A IL 26179218A IL 261792 B IL261792 B IL 261792B
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163178 | 2016-03-31 | ||
| PCT/EP2017/057775 WO2017167997A1 (en) | 2016-03-31 | 2017-03-31 | Compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL261792A IL261792A (en) | 2018-10-31 |
| IL261792B true IL261792B (en) | 2022-06-01 |
Family
ID=55646428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261792A IL261792B (en) | 2016-03-31 | 2018-09-16 | Preparations |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10772839B2 (https=) |
| EP (1) | EP3435982A1 (https=) |
| JP (2) | JP7224917B2 (https=) |
| KR (1) | KR102376369B1 (https=) |
| CN (2) | CN117243904A (https=) |
| AU (2) | AU2017240190A1 (https=) |
| CA (2) | CA3019482A1 (https=) |
| IL (1) | IL261792B (https=) |
| SG (1) | SG11201807402PA (https=) |
| WO (2) | WO2017167997A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188223B2 (en) * | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| CA3255406A1 (en) * | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| SG11201706840WA (en) | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| SG11201807402PA (en) | 2016-03-31 | 2018-09-27 | Vhsquared Ltd | Compositions |
| EP3519438A1 (en) * | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| CN110430801B (zh) | 2016-12-14 | 2024-04-30 | 比奥拉治疗股份有限公司 | 使用tnf抑制剂治疗胃肠道疾病 |
| WO2018183929A1 (en) * | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| WO2020144164A1 (en) | 2019-01-07 | 2020-07-16 | Bactolife Aps | Pathogen binding proteins |
| WO2020243393A1 (en) * | 2019-05-30 | 2020-12-03 | Vta Labs, Llc | Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis |
| US12559552B2 (en) | 2019-06-21 | 2026-02-24 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021233296A1 (zh) * | 2020-05-18 | 2021-11-25 | 深圳市塔吉瑞生物医药有限公司 | 大环化合物的固体形式及其制备和用途 |
| CN113768051B (zh) * | 2020-06-09 | 2024-03-19 | 中粮营养健康研究院有限公司 | 饲料添加剂及其制备方法和其在饲料中的应用以及替抗饲料 |
| GB202017863D0 (en) * | 2020-11-12 | 2020-12-30 | Intract Pharma Ltd | Novel compositions |
| WO2024163874A2 (en) * | 2023-02-03 | 2024-08-08 | Avexegen Therapeutics, Inc. | Stable and controlled release formulations of neuregulin-4 analogs |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2010126A (en) | 1934-03-19 | 1935-08-06 | Frank L Mclaughlin | Measuring and dispensing can |
| DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
| DE69432309D1 (de) * | 1993-09-20 | 2003-04-24 | Anadis Ltd | Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen |
| CN1116898C (zh) * | 2000-02-21 | 2003-08-06 | 湖北楚冠实业股份有限公司 | 一种口服免疫球蛋白制剂及其制备方法 |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| BRPI0516681A (pt) * | 2004-11-25 | 2008-09-16 | Unilever Nv | sistema de entrega de anticorpos ao trato gastrointestinal, vetor de expressão, microorganismos transformados, método de entrega de anticorpos, imunoglobulinas de cadeia pesada e seu uso, produto alimentìcio e seu método de fabricação e utensìlio de distribuição |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| US20080026820A1 (en) * | 2006-07-05 | 2008-01-31 | Aruze Gaming America, Inc. | Slot machine and playing method thereof |
| MX2009002756A (es) | 2006-09-12 | 2009-05-25 | Cosmo Technologies Ltd | Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas. |
| US20100129379A1 (en) | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| US20080145420A1 (en) | 2006-12-13 | 2008-06-19 | Simon Michael R | HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES |
| US8246950B2 (en) * | 2007-02-20 | 2012-08-21 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
| ES2393814T3 (es) * | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| US20100239682A1 (en) | 2007-09-17 | 2010-09-23 | Antoine Andremont | Colonic delivery of antimicrobial agents |
| US20090149433A1 (en) | 2007-11-13 | 2009-06-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| CA2738243C (en) | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| US9056050B2 (en) * | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| CN101964403A (zh) | 2009-07-23 | 2011-02-02 | 比克国际(天津)有限公司 | 一种电池组的封装方法及电池组 |
| EP3603624A1 (en) | 2009-12-24 | 2020-02-05 | Rani Therapeutics, LLC | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP2533814A2 (en) | 2010-02-11 | 2012-12-19 | Ablynx N.V. | Delivery of immunoglobulin variable domains and constructs thereof |
| NZ602685A (en) | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
| AU2012234282B2 (en) | 2011-03-28 | 2015-07-16 | Ablynx Nv | Method for producing solid formulations comprising immunoglobulin single variable domains |
| EP2849723B1 (en) | 2012-05-18 | 2018-05-02 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
| BR112015003851A2 (pt) * | 2012-08-21 | 2017-08-08 | Glaxo Group Ltd | composições compreendendo um domínio variável único e mesilato de camostato (cm) |
| AU2014229282B2 (en) | 2013-03-15 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| US20160228371A1 (en) | 2013-10-18 | 2016-08-11 | Abbvie Inc. | Stable solid units and methods of making the same |
| US10220076B2 (en) | 2014-05-15 | 2019-03-05 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins |
| FR3026012B1 (fr) * | 2014-09-23 | 2017-12-01 | Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic | Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique |
| CA3255406A1 (en) * | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| SG11201807402PA (en) | 2016-03-31 | 2018-09-27 | Vhsquared Ltd | Compositions |
-
2017
- 2017-03-31 SG SG11201807402PA patent/SG11201807402PA/en unknown
- 2017-03-31 CA CA3019482A patent/CA3019482A1/en active Pending
- 2017-03-31 JP JP2018551137A patent/JP7224917B2/ja active Active
- 2017-03-31 EP EP17716044.7A patent/EP3435982A1/en active Pending
- 2017-03-31 AU AU2017240190A patent/AU2017240190A1/en not_active Abandoned
- 2017-03-31 WO PCT/EP2017/057775 patent/WO2017167997A1/en not_active Ceased
- 2017-04-03 WO PCT/MT2017/000001 patent/WO2017171535A2/en not_active Ceased
- 2017-04-03 CN CN202311230166.8A patent/CN117243904A/zh active Pending
- 2017-04-03 CN CN201780020634.5A patent/CN109152738B/zh active Active
- 2017-04-03 KR KR1020187029576A patent/KR102376369B1/ko active Active
- 2017-04-03 CA CA3053757A patent/CA3053757A1/en not_active Abandoned
-
2018
- 2018-09-16 IL IL261792A patent/IL261792B/en unknown
- 2018-09-25 US US16/140,843 patent/US10772839B2/en active Active
-
2020
- 2020-08-07 US US16/988,506 patent/US10980748B2/en active Active
-
2023
- 2023-01-24 AU AU2023200377A patent/AU2023200377B2/en active Active
- 2023-02-08 JP JP2023017273A patent/JP7496906B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023200377A1 (en) | 2023-02-23 |
| US20200368167A1 (en) | 2020-11-26 |
| CN109152738A (zh) | 2019-01-04 |
| AU2023200377B2 (en) | 2025-04-10 |
| EP3435982A1 (en) | 2019-02-06 |
| WO2017171535A8 (en) | 2017-11-16 |
| JP2019514855A (ja) | 2019-06-06 |
| CN109152738B (zh) | 2023-10-13 |
| CA3053757A1 (en) | 2017-10-05 |
| IL261792A (en) | 2018-10-31 |
| AU2017240190A1 (en) | 2018-09-20 |
| KR102376369B1 (ko) | 2022-03-18 |
| JP2023058591A (ja) | 2023-04-25 |
| KR20190003493A (ko) | 2019-01-09 |
| JP7224917B2 (ja) | 2023-02-20 |
| CN117243904A (zh) | 2023-12-19 |
| WO2017171535A3 (en) | 2017-12-07 |
| CA3019482A1 (en) | 2017-10-05 |
| WO2017167997A1 (en) | 2017-10-05 |
| US20190008778A1 (en) | 2019-01-10 |
| US10980748B2 (en) | 2021-04-20 |
| US10772839B2 (en) | 2020-09-15 |
| WO2017171535A2 (en) | 2017-10-05 |
| JP7496906B2 (ja) | 2024-06-07 |
| SG11201807402PA (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261792B (en) | Preparations | |
| IL260933A (en) | Preparations containing tocorsol or its analogues | |
| GB201610156D0 (en) | Cliptac compositions | |
| SG11201705415YA (en) | Multi-supplement compositions | |
| IL257131A (en) | Preparations | |
| GB201515387D0 (en) | Compositions | |
| GB201501598D0 (en) | Compositions | |
| IL256559B1 (en) | Flinbolin preparations | |
| GB201515391D0 (en) | Compositions | |
| SI3349766T1 (sl) | Antihemoragični sestavki | |
| GB201600075D0 (en) | Immunogenci composition | |
| GB201622161D0 (en) | Compositions | |
| GB201614799D0 (en) | Compositions | |
| GB201610628D0 (en) | New compositions | |
| GB2538335B (en) | Compositions | |
| GB201616654D0 (en) | Composition | |
| GB201602658D0 (en) | Compositions | |
| GB201602579D0 (en) | New compositions | |
| HUE050837T2 (hu) | Készítmények | |
| GB201607924D0 (en) | Composition | |
| GB201614230D0 (en) | Compositions | |
| GB201611960D0 (en) | Compositions | |
| GB201611851D0 (en) | Compositions | |
| GB201602656D0 (en) | Compositions | |
| GB201618062D0 (en) | Composition |